OK some are listening. Buyouts mean loss of jobs, which means people will be voted out of Parliament or some street action

From the WSJ review in total UK M&A Surge Down to More than Sterling Updated July 18 2016 5:46 pm BST Photo: Bloomberg News The steep fall in the pound after last month’s Brexit vote has UK boardrooms on guard for opportunistic foreign bidders. But while there has been a raft of deals since the June 23 referendum to leave the European Union, they have been a lot more complicated than simple bargain hunting. • Last week, Chinese conglomerate Dalian Wanda Group said its US-based cinema operator unit AMC Entertainment Holdings agreed to buy Europe’s largest cinema chain, Britain-based Odeon & UCI Cinemas Group, for £500 million. It said the lower pound was a major factor, and AMC’s chief executive warned ”there may even be a stampede of US acquirers looking at the United Kingdom.” • The same week, Poundland said it had agreed to a £600-million takeover offer from South African-based, German-listed Steinhoff International. A spokesman declined to comment on whether Brexit played a role, but said discussions were underway long before the vote. • And the first big cross-border deal following the referendum was one in which the money flow was going in the opposite direction: In early July, Melrose said it would buy US-listed Nortek for $1.44 billion in cash. The SoftBank deal underscores the complexity. ARM makes almost all of its revenue outside Britain, and its share price has soared since the vote. At Friday’s close, its stock was 17% more expensive than on referendum day. That more than offset the roughly 13% drop of the pound versus the yen since then. That means SoftBank probably would have paid less for ARM if it had clinched the deal prior to the June 23 vote. Another question that bankers and deal makers have asked themselves about potential targets in Britain: How will the new government of Prime Minister Theresa May react? She struck a cautious tone about foreign takeovers of leading UK companies in a speech last week. On Monday, British officials welcomed the SoftBank deal. The Japanese firm promised to keep ARM based in England and double its UK-based workforce. Officials said it was a sign British businesses were still attractive to overseas investors despite Brexit. Not everyone agreed. Opposition Labour MP Daniel Zeichner, who represents Cambridge, where ARM is based, said the deal meant Britain was ”losing control of one of our most innovative and successful companies,” and called on the government to secure a guarantee from SoftBank on a job-creation pledge.

One countries' trash is another's treasure

I do not believe that the English legislators realized what they were doing when they voted to exit the EU. Let me say this in a few words. If I were the President of Gilead , I would see to it that the US initiates a part in an INTERNATIONAL medicine Union and gain voting power now , before the last knockout punch was delivered. Nuff Said. Let me have a line of credit with my limited German and Good French and Spanish and I will lead the Group, putting in Chinese medicines a South American and last but not least AFRICAN medicines, for the befit of MANKIND not just Europe

One countries' trash is another's treasure

I do not believe that the English legislators realized what they were doing when they voted to exit the EU. Let me say this in a few words. If I were the President of Gilead , I would see to it that the US initiates a part in an INTERNATIONAL medicine Union and gain voting power now , before the last knockout punch was delivered. Nuff Said. Let me have a line of credit with my limited German and Good French and Spanish and I will lead the Group, putting in Chinese medicines a South American and last but not least AFRICAN medicines, for the befit of MANKIND not just Europe

Ferce pub finest word for word

The European Medicines Agency, the drug regulator for Europe, is headquartered in London. The problem is that the U.K. voted Thursday to leave the European Union, meaning the EMA will now have to leave and find a new home. It is one of the countless concerns that affect the pharma industry with Britain’s historic vote to give up on European unity. Over the warnings of business leaders in pharma and all other industries, U.K. voters by a 52% to 48% margin opted to quit the E.U. While the vote is not even legally binding, U.K Prime Minister David Cameron has said he would do as voters decided. He has pledged to resign. The financial reaction was immediate and messy. The London FTSE 100 index sank by 8%, the biggest fall in more than three decades, before recovering slightly to trade down 5%. The broader FTSE 250 index has dropped 7.5%. The pound hit its lowest level against the dollar in 31 years touching $1.3236, as investors tried to puzzle through what the vote means for businesses. While the drops were dramatic, Evercore ISI analyst Mark Schoenebaum pointed out to investors that most major drugmakers derive less than 3% of their revenues from sales in the U.K. And not all investors were panicked by the decision. Pharma investment specialist Neil Woodford said in a statement “in our view, it is not as negative a development as the market's initial react appears to imply." Woodford, who has backed a breakup of U.K.-based GlaxoSmithKline, acknowledges there are uncertainties and challenges, but thinks the industry faces a lot more than whether the U.K. is a member of the European Union. ”Many of the greatest economic challenges that we face now and in the future, in my view, dwarf the economic issues associated with today’s outcome.” That is the future but for now, everyone is focused on figuring out how their particular concerns will be affected. Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association, in a statement pointed to the benefits that a single European marketing authorization has had for drugmakers and Britain's National Health System by reducing complexity and cost for drugmakers. He raised the possibility that the U.K. would continue to work through the EMA. “The UK generic and biosimilar medicines industry therefore urges the government to do everything possible to maintain this European marketing authorisation system in the forthcoming negotiations with the European Union,” Smith said. Global legal experts Dechert parse the concerns in more concrete terms. The firm pointed out that, besides being home to the European Medicines Agency, the U.K. has provided a voice for industry at the EU table that will now be lost. On a more practical level, Dechert said businesses must figure out what the move means to trade agreements which affect their supply chains, and the tariffs involved. For intellectual property, it said that trademark owners that have relied on an EU approval may lose their protection until they can convert to a U.K. trademark, which will come at additional cost. The vote may affect the future of the “unitary patent,” which was to go into effect when the Agreement on the Unified Patent Court went into force. Dechert does point out that not all these things have to be figured out immediately. Once U.K. officially notifies the European Council its intention to leave, EU treaties have a two-year time limit for the exit to begin and can be extended if all sides agree. The treaties do not set a time limit for the U.K. and EU to remake its relationship. As for the EMA, there is little doubt that it will find a new home, even though it just moved into its new building two years ago. Already, officials in Italy, Sweden and Denmark have all expressed interest in taking over as host country, Politico reports. One of those to step forward was, Luca Pani, director general of Italy’s drugs agency AIFA, Politico said. He pointed out that the current head of the EMA, Guido Rasi, is from Italy and spent his career at AIFA before being named director of the EMA. “We are firmly convinced that Italy would make an ideal candidate to host the European Medicine agency,” he told Politico earlier this year.

The antithesis of trust

Who do you trust? My trust is built on nothing less than Jesus' blood and righteousness. Anyone betting against EU and British stocks 3 months ago is very rich and either very smart or .... Please look at the dollar price. Please consider the $10,000,000,000 settlement with Volkswagen. How timely? For who? From WSJ

Barclays, which has seen its share price slump 30% since last Thursday, finds itself in the eye of the storm. Following his arrival last year, chief executive Jes Staley pledged Barclays would remain diversified with a sizable investment bank and that his team could boil down ​a mountain​​ of unwanted assets by 2017. Analysts say that the uncertainty around Brexit could hamper the bank’s plan to cut costs as it may have to relocate certain investment banking operations outside the UK. It could also dull investor appetite for some unwanted assets. “It puts a spanner in the works,” says Joseph Dickerson, a banks analyst at Jefferies. Barclays currently has no plan to alter its strategy, according to one senior executive. Around 60% of Barclays’ investment banking revenue comes from the US, and a fall in sterling makes dollar generated revenues more valuable. So far, volumes in foreign currency trading have managed to offset falls in other products across Europe and plans to sell down its “noncore” unit are on track, the executive added. Read the full story on WSJ.com city@wsj.com